Cargando…

Treatment Choices in Managing Bethesda III and IV Thyroid Nodules: A Canadian Multi-institutional Study

OBJECTIVE: Patient-centered decision making is increasingly identified as a desirable component of medical care. To manage indeterminate thyroid nodules, patients are offered the options of surveillance, diagnostic hemithyroidectomy, or molecular testing. Our objective was to identify factors associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuta, Victoria, Forner, David, Azzi, Jason, Curry, Dennis, Noel, Christopher W., Munroe, Kelti, Bullock, Martin, McDonald, Ted, Taylor, S. Mark, Rigby, Matthew H., Trites, Jonathan, Johnson-Obaseki, Stephanie, Corsten, Martin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239982/
https://www.ncbi.nlm.nih.gov/pubmed/34250424
http://dx.doi.org/10.1177/2473974X211015937
_version_ 1783715129191301120
author Kuta, Victoria
Forner, David
Azzi, Jason
Curry, Dennis
Noel, Christopher W.
Munroe, Kelti
Bullock, Martin
McDonald, Ted
Taylor, S. Mark
Rigby, Matthew H.
Trites, Jonathan
Johnson-Obaseki, Stephanie
Corsten, Martin J.
author_facet Kuta, Victoria
Forner, David
Azzi, Jason
Curry, Dennis
Noel, Christopher W.
Munroe, Kelti
Bullock, Martin
McDonald, Ted
Taylor, S. Mark
Rigby, Matthew H.
Trites, Jonathan
Johnson-Obaseki, Stephanie
Corsten, Martin J.
author_sort Kuta, Victoria
collection PubMed
description OBJECTIVE: Patient-centered decision making is increasingly identified as a desirable component of medical care. To manage indeterminate thyroid nodules, patients are offered the options of surveillance, diagnostic hemithyroidectomy, or molecular testing. Our objective was to identify factors associated with decision making in this population. STUDY DESIGN: This is a retrospective cross-sectional study of patients with Bethesda III and IV thyroid nodules. SETTING: Multi-institutional. METHODS: Factors of interest included age, sex, socioeconomic status (SES), nodule size, institution, attending surgeon, surgeon payment model, and hospital type. Our outcome of interest was the initial management decision made by patients. RESULTS: A total of 956 patients were included. The majority of patients had Bethesda III nodules (n = 738, 77%). A total of 538 (56%) patients chose surgery, 413 (43%) chose surveillance, and 5 (1%) chose molecular testing. There was a significant variation in management decision based on attending surgeon (proportion of patients choosing surgery: 15%-83%; P≤.0001). Fee-for-service surgeon payment models (odds ratio [OR], 1.657; 95% CI, 1.263-2.175; P < .001) and community hospital settings (OR, 1.529; 95% CI, 1.145-2.042; P < .001) were associated with the decision for surgery. Larger nodule size, younger patients, and Bethesda IV nodules were also associated with surgery. CONCLUSION: While it seems appropriate that larger nodules, younger age, and higher Bethesda class were associated with decision for surgery, we also identified attending surgeon, surgeon payment model, and hospital type as important factors. Given this, standardizing management discussions may improve patient-centered shared decision making.
format Online
Article
Text
id pubmed-8239982
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-82399822021-07-08 Treatment Choices in Managing Bethesda III and IV Thyroid Nodules: A Canadian Multi-institutional Study Kuta, Victoria Forner, David Azzi, Jason Curry, Dennis Noel, Christopher W. Munroe, Kelti Bullock, Martin McDonald, Ted Taylor, S. Mark Rigby, Matthew H. Trites, Jonathan Johnson-Obaseki, Stephanie Corsten, Martin J. OTO Open Original Research OBJECTIVE: Patient-centered decision making is increasingly identified as a desirable component of medical care. To manage indeterminate thyroid nodules, patients are offered the options of surveillance, diagnostic hemithyroidectomy, or molecular testing. Our objective was to identify factors associated with decision making in this population. STUDY DESIGN: This is a retrospective cross-sectional study of patients with Bethesda III and IV thyroid nodules. SETTING: Multi-institutional. METHODS: Factors of interest included age, sex, socioeconomic status (SES), nodule size, institution, attending surgeon, surgeon payment model, and hospital type. Our outcome of interest was the initial management decision made by patients. RESULTS: A total of 956 patients were included. The majority of patients had Bethesda III nodules (n = 738, 77%). A total of 538 (56%) patients chose surgery, 413 (43%) chose surveillance, and 5 (1%) chose molecular testing. There was a significant variation in management decision based on attending surgeon (proportion of patients choosing surgery: 15%-83%; P≤.0001). Fee-for-service surgeon payment models (odds ratio [OR], 1.657; 95% CI, 1.263-2.175; P < .001) and community hospital settings (OR, 1.529; 95% CI, 1.145-2.042; P < .001) were associated with the decision for surgery. Larger nodule size, younger patients, and Bethesda IV nodules were also associated with surgery. CONCLUSION: While it seems appropriate that larger nodules, younger age, and higher Bethesda class were associated with decision for surgery, we also identified attending surgeon, surgeon payment model, and hospital type as important factors. Given this, standardizing management discussions may improve patient-centered shared decision making. SAGE Publications 2021-06-24 /pmc/articles/PMC8239982/ /pubmed/34250424 http://dx.doi.org/10.1177/2473974X211015937 Text en © The Authors 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Kuta, Victoria
Forner, David
Azzi, Jason
Curry, Dennis
Noel, Christopher W.
Munroe, Kelti
Bullock, Martin
McDonald, Ted
Taylor, S. Mark
Rigby, Matthew H.
Trites, Jonathan
Johnson-Obaseki, Stephanie
Corsten, Martin J.
Treatment Choices in Managing Bethesda III and IV Thyroid Nodules: A Canadian Multi-institutional Study
title Treatment Choices in Managing Bethesda III and IV Thyroid Nodules: A Canadian Multi-institutional Study
title_full Treatment Choices in Managing Bethesda III and IV Thyroid Nodules: A Canadian Multi-institutional Study
title_fullStr Treatment Choices in Managing Bethesda III and IV Thyroid Nodules: A Canadian Multi-institutional Study
title_full_unstemmed Treatment Choices in Managing Bethesda III and IV Thyroid Nodules: A Canadian Multi-institutional Study
title_short Treatment Choices in Managing Bethesda III and IV Thyroid Nodules: A Canadian Multi-institutional Study
title_sort treatment choices in managing bethesda iii and iv thyroid nodules: a canadian multi-institutional study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239982/
https://www.ncbi.nlm.nih.gov/pubmed/34250424
http://dx.doi.org/10.1177/2473974X211015937
work_keys_str_mv AT kutavictoria treatmentchoicesinmanagingbethesdaiiiandivthyroidnodulesacanadianmultiinstitutionalstudy
AT fornerdavid treatmentchoicesinmanagingbethesdaiiiandivthyroidnodulesacanadianmultiinstitutionalstudy
AT azzijason treatmentchoicesinmanagingbethesdaiiiandivthyroidnodulesacanadianmultiinstitutionalstudy
AT currydennis treatmentchoicesinmanagingbethesdaiiiandivthyroidnodulesacanadianmultiinstitutionalstudy
AT noelchristopherw treatmentchoicesinmanagingbethesdaiiiandivthyroidnodulesacanadianmultiinstitutionalstudy
AT munroekelti treatmentchoicesinmanagingbethesdaiiiandivthyroidnodulesacanadianmultiinstitutionalstudy
AT bullockmartin treatmentchoicesinmanagingbethesdaiiiandivthyroidnodulesacanadianmultiinstitutionalstudy
AT mcdonaldted treatmentchoicesinmanagingbethesdaiiiandivthyroidnodulesacanadianmultiinstitutionalstudy
AT taylorsmark treatmentchoicesinmanagingbethesdaiiiandivthyroidnodulesacanadianmultiinstitutionalstudy
AT rigbymatthewh treatmentchoicesinmanagingbethesdaiiiandivthyroidnodulesacanadianmultiinstitutionalstudy
AT tritesjonathan treatmentchoicesinmanagingbethesdaiiiandivthyroidnodulesacanadianmultiinstitutionalstudy
AT johnsonobasekistephanie treatmentchoicesinmanagingbethesdaiiiandivthyroidnodulesacanadianmultiinstitutionalstudy
AT corstenmartinj treatmentchoicesinmanagingbethesdaiiiandivthyroidnodulesacanadianmultiinstitutionalstudy